BRIDGEWATER, N.J., April 7, 2026
Insmed Incorporated has announced that its Phase 2b CEDAR clinical trial evaluating brensocatib in hidradenitis suppurativa (HS) did not meet its primary or secondary efficacy endpoints, leading to the discontinuation of the HS development program despite a favorable safety profile. The results highlight the complex challenges in developing effective therapies for inflammatory skin diseases, while providing valuable insights for future research.
Phase 2b Trial Fails to Demonstrate Clinical Efficacy
The CEDAR study, a randomized, double-blind, placebo-controlled Phase 2b clinical trial, was designed to evaluate the efficacy and safety of brensocatib in adult patients with moderate to severe HS. Despite encouraging expectations, the trial failed to achieve its primary endpoint, which was percentage reduction in abscess and inflammatory nodule count at Week 16.
Clinical data showed that patients receiving brensocatib experienced reductions in inflammatory lesions, but these improvements were not superior to placebo. In fact, the placebo group demonstrated a greater reduction in lesion count compared to both treatment arms, indicating that the therapy did not provide a meaningful clinical benefit in this indication.
The study enrolled 214 patients across 72 global sites, reflecting a robust clinical design. However, the results underscore the difficulty of translating mechanistic promise into clinical efficacy, particularly in diseases like HS where biological pathways are not fully understood.
Advertisement
Favorable Safety Profile Despite Lack of Efficacy
Although the trial did not meet efficacy endpoints, brensocatib demonstrated a strong safety profile, with no new safety signals identified across both dose groups. Treatment-emergent adverse events were consistent with previous studies, and the drug was generally well tolerated even at the highest tested dose of 40 mg.
This safety consistency reinforces the potential of brensocatib in other therapeutic areas, where it may still provide clinical benefit. The absence of significant safety concerns is particularly important in drug development, as it allows for continued exploration of the compound in alternative indications.
Insmed emphasized that while the outcome is disappointing, the data generated will contribute to a broader scientific understanding of hidradenitis suppurativa, a disease with limited treatment options and complex pathophysiology.
Strategic Shift and Future Development Focus
Following the trial results, Insmed has decided to discontinue further development of brensocatib for HS, marking a strategic shift in its clinical pipeline. The company plans to present detailed findings at a future scientific congress, ensuring that the insights gained from the study are shared with the broader research community.
Despite this setback, Insmed continues to advance a diverse portfolio of investigational therapies, focusing on pulmonary and inflammatory diseases, as well as emerging technologies such as gene therapy, AI-driven protein engineering, and RNA-based approaches.
The outcome of the CEDAR study highlights the importance of rigorous clinical evaluation and adaptive development strategies in the biopharmaceutical industry. Even unsuccessful trials provide critical data that can guide future innovation and improve the understanding of complex diseases.
The Phase 2b CEDAR study results represent a significant but informative milestone in Insmed’s clinical development journey, demonstrating that while brensocatib is safe, it does not provide sufficient efficacy in hidradenitis suppurativa. The decision to discontinue the HS program reflects a data-driven approach to pipeline optimization, allowing the company to focus on more promising therapeutic opportunities while contributing valuable knowledge to the scientific community.
Source: Insmed press release
